Literature DB >> 9710889

Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis.

A F Kavanaugh1.   

Abstract

Because it plays a central role in the immunopathogenesis of rheumatoid arthritis (RA), TNF-alpha is an attractive target for immunomodulatory therapy. In a number of rigorous studies, monoclonal antibodies (mAb) specific for TNF-alpha have proved efficacious in patients with active RA. Data from these studies and issues related to mechanisms of action, potential toxicity, and future directions for this novel therapeutic approach are considered in this review.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9710889     DOI： 10.1016/s0889-857x(05)70028-4

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  28 in total

Review 1.  Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7.

Authors:  J Kempeni
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Access to disease modifying treatments for rheumatoid arthritis patients.

Authors:  D E Furst; F C Breedveld; G R Burmester; L Crofford; P Emery; M Feldman; J R Kalden; A Kavanaugh; E Keystone; P E Lipsky; R N Maini; L Moreland; J S Smolen; L Van De Putte; T Vischer; M Weinblatt; M Weissman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

3.  Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?

Authors:  J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 4.  Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody.

Authors:  J Kempeni
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 5.  Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors:  N Fathy; D E Furst
Journal:  Springer Semin Immunopathol       Date:  2001

6.  Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up.

Authors:  E Kruithof; F Van den Bosch; D Baeten; A Herssens; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

Review 7.  Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.

Authors:  F Van den Bosch; D Baeten; E Kruithof; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 8.  Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; C E Antoni; J W J Bijlsma; G R Burmester; B Cronstein; E C Keystone; A Kavanaugh; L Klareskog
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 9.  Ankylosing spondylitis: introductory comments on its diagnosis and treatment.

Authors:  M A Khan
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

10.  Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.

Authors:  F Van den Bosch; E Kruithof; D Baeten; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.